Overall rank by patents
#31,812
Across all tracked assignees
USPTO PatentsView assignee record - 8 granted patents across 7 technology areas, active 2015–2020. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A46B (BRUSHES).
The verdict
Glaxosmithkline holds 8 US patents across 7 technology areas, rank #31,812 of 50,000 tracked assignees.
Glaxosmithkline Consumer Healthcare Gmbh And Co. KG has been granted 8 US utility patents between 2015 and 2020, placing Glaxosmithkline Consumer Healthcare Gmbh And Co. KG at rank #31,812 across all assignees tracked by PlainPatent. This portfolio spans 7 distinct Cooperative Patent Classification (CPC) subclasses, averaging 8.5 claims per patent with primary concentration in A46B (BRUSHES). As a Foreign Corporation, Glaxosmithkline Consumer Healthcare Gmbh And Co. KG is one of the more focused assignees in the PatentsView dataset. By volume, Glaxosmithkline sits between Gifu Plastic Industry Co. Ltd. (8 patents, rank #31,808) and Glysens Incorporated (8 patents, rank #31,816) - the closest US assignees by grant volume. The composite Innovation Score of 22.0/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 1 grants, compared with 7 in the 2015–2019 window, a -86% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Glaxosmithkline Consumer Healthcare Gmbh And Co. KG's 8.5 average claims per patent suggests focused, narrowly drawn claims typical of single-invention filings, while concentration in 7 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Glaxosmithkline Consumer Healthcare Gmbh And Co. KG against peers pursuing similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
Gifu Plastic Industry Co. Ltd.
8 patents
Ginsey Industries, Inc.
8 patents
Giti Radial Tire (ANHUI) Company LTD.
8 patents
Glam Labs, Inc.
8 patents
Glean Technologies, Inc.
8 patents
Global Algae Technology, LLC
8 patents
Global Energy Science, LLC
8 patents
GlySens Incorporated
8 patents
GlaxoSmithKline Consumer Healthcare GmbH and Co. KG
8 patents
What this shows Glaxosmithkline holds 8 patents at rank #31,812, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #31,812 in granted patent volume.
Other assignees with the most granted patents in Glaxosmithkline's primary technology class.
Glaxosmithkline's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
22 Top 90% higher than 10% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 2 | 25.0% |
| 2016 | 1 | 12.5% |
| 2017 | 2 | 25.0% |
| 2018 | 2 | 25.0% |
| 2020 | 1 | 12.5% |
Top 7 of 7 technology areas
Overall rank by patents
#31,812
Across all tracked assignees
22.0 out of 100
How to use this portfolio
Glaxosmithkline's 8 grants land it in the top 90% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.